Please login to the form below

Not currently logged in
Email:
Password:

human growth hormone

This page shows the latest human growth hormone news and features for those working in and with pharma, biotech and healthcare.

NICE gives Lilly’s Verzenios chance to compete with rivals

NICE gives Lilly’s Verzenios chance to compete with rivals

Verzenios (abemaciclib) has been recommended in draft guidance by NICE in combination with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or ... This is for another

Latest news

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Implementing eHealth innovation Implementing eHealth innovation

    Medications management and eHealth. The reference treatment for patients with GHD is based on recombinant human growth hormone (rhGH) which is identical to the growth hormone produced by the pituitary gland. ... growth hormone deficiency, one in which

  • Pharma deals during December 2014 Pharma deals during December 2014

    costs. Pfizer has also signed up to a drug delivery product this month through its $570m licensing deal with Opko Health for a long acting version of human growth hormone (hGH), ... which is currently in phase III trials for the treatment of growth

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Pharma and free medicines: a different perspective

    Palbociclib is approved for the treatment of patients with locally advanced or metastatic breast cancer, specifically those who have hormone receptor-positive and human epidermal growth factor receptor 2-negative disease. ... The committee found that

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics